S. Krishnaswami
About
S. Krishnaswami is a scholar working on Rheumatology, Immunology and Genetics.
According to data from OpenAlex, S. Krishnaswami has authored 31 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Rheumatology, 11 papers in Immunology and 10 papers in Genetics. Recurrent topics in S. Krishnaswami's work include Rheumatoid Arthritis Research and Therapies (18 papers), Chronic Lymphocytic Leukemia Research (10 papers) and Autoimmune and Inflammatory Disorders Research (6 papers). S. Krishnaswami is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (18 papers), Chronic Lymphocytic Leukemia Research (10 papers) and Autoimmune and Inflammatory Disorders Research (6 papers). S. Krishnaswami collaborates with scholars based in United States, United Kingdom and Canada. S. Krishnaswami's co-authors include Priya Gupta, Samapti Guha, Pankaj Gupta, Huaming Tan, Robert Wołk, Kim Papp, Alan Menter, Bruce Strober, Jane Harness and M. Buonanno and has published in prestigious journals such as Annals of the Rheumatic Diseases, Transplantation and Clinical Pharmacology & Therapeutics.
In The Last Decade
S. Krishnaswami
30 papers receiving 1.1k citations
Peers
S. Krishnaswami
Mark Peterson United States
Edwin B. Cox United States
Randall E. Millikan United States
Denise Williams United States
Albiruni R. Abdul Razak Canada
Ivo Kocák Czechia
Rastislav Bahleda France
Liji Shen United States
Norbert Hollaender Switzerland
J. Thaddeus Beck United States
Citations per year, relative to S. Krishnaswami S. Krishnaswami (= 1×)
peers
Mark Peterson
Countries citing papers authored by S. Krishnaswami
Since
Specialization
Citations
This map shows the geographic impact of S. Krishnaswami's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Krishnaswami with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Krishnaswami more than expected).
Fields of papers citing papers by S. Krishnaswami
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by S. Krishnaswami. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Krishnaswami. The network helps show where S. Krishnaswami may publish in the future.
Co-authorship network of co-authors of S. Krishnaswami
This figure shows the co-authorship network connecting the top 25 collaborators of S. Krishnaswami. A scholar is included among the top collaborators of S. Krishnaswami based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. Krishnaswami. S. Krishnaswami is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Charles‐Schoeman, Christina, Joel M. Kremer, S. Krishnaswami, et al.. (2017). THU0185 Comparison of tofacitinib safety and efficacy in rheumatoid arthritis patients with inadequate response to conventional synthetic dmards, or to one or more biological dmards. Annals of the Rheumatic Diseases. 76. 271–272.
2.
Strand, Vibeke, Sima Ahadieh, Ryan DeMasi, et al.. (2017). THU0211 Meta-analysis of serious infections with baricitinib, tofacitinib and biologic dmards in rheumatoid arthritis. Annals of the Rheumatic Diseases. 76. 284–284.
3.
Ahadieh, Sima, Pankaj Gupta, Jaap W. Mandema, et al.. (2017). Quantitative Evaluations of Time‐Course and Treatment Effects of Systemic Agents for Psoriasis: A Model‐Based Meta‐Analysis. Clinical Pharmacology & Therapeutics. 102(6). 1006–1016.
4.
Geier, Jamie, et al.. (2017). THU0196 Systematic review and meta-analysis of malignancies, excluding non-melanoma skin cancer, in patients with rheumatoid arthritis treated with tofacitinib or biologic disease-modifying antirheumatic drugs. Annals of the Rheumatic Diseases. 76. 277–277.
5.
Papp, Kim, S. Krishnaswami, Kaori Ito, et al.. (2017). Evaluating Dosage Optimality for Tofacitinib, an Oral Janus Kinase Inhibitor, in Plaque Psoriasis, and the Influence of Body Weight. CPT Pharmacometrics & Systems Pharmacology. 6(5). 322–330.
6.
Vollenhoven, Ronald van, Ernest Choy, Irina Lazariciu, et al.. (2016). THU0199 Tofacitinib, An Oral Janus Kinase Inhibitor, in The Treatment of Rheumatoid Arthritis: Changes in Lymphocytes and Lymphocyte Subset Counts and Reversibility after Up To 8 Years of Tofacitinib Treatment. Annals of the Rheumatic Diseases. 75. 258–258.
7.
Boyle, D L, Arthur Kavanaugh, David R. Mandel, et al.. (2014). The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis. Annals of the Rheumatic Diseases. 74(6). 1311–1316.
8.
Kawabata, Thomas T., Wichard Vogel, Richard J. Riese, et al.. (2014). AB0474 Changes in T and B Lymphocyte Subsets with Tofacitinib do not Translate from Nonclinical Species to Humans. Annals of the Rheumatic Diseases. 73. 964–965.
9.
Strand, Vibeke, John D. Isaacs, James R. Beal, et al.. (2014). THU0145 Association of Mean Changes in Laboratory Safety Parameters with C-Reactive Protein at Baseline and Week 12 in Rheumatoid Arthritis Patients Treated with Tofacitinib. Annals of the Rheumatic Diseases. 73. 229–229.
10.
Milligan, Peter A., B Marchant, Steven W. Martin, et al.. (2013). Model-Based Drug Development: A Rational Approach to Efficiently Accelerate Drug Development. Clinical Pharmacology & Therapeutics. 93(6). 502–514.
11.
Gupta, Priya, Samapti Guha, & S. Krishnaswami. (2013). Firm growth and its determinants. Journal of Innovation and Entrepreneurship. 2(1). 15–15.
12.
Tan, Huaming, Pankaj Gupta, Jane Harness, et al.. (2013). Dose Response and Pharmacokinetics of Tofacitinib (CP‐690,550), an Oral Janus Kinase Inhibitor, in the Treatment of Chronic Plaque Psoriasis. CPT Pharmacometrics & Systems Pharmacology. 2(5). 1–8.
13.
Heijde, D. van der, Yoshiya Tanaka, R Fleischmann, et al.. (2012). Tofacitinib, an Oral Janus Kinase Inhibitor, in Combination with Methotrexate Reduced the Progression of Structural Damage in Patients with Rheumatoid Arthritis: Year 2 Efficacy and Safety Results From a 24-Month Phase 3 Study. Arthritis & Rheumatism. 64(10).
14.
Papp, Kim, Alan Menter, Bruce Strober, et al.. (2012). Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study. British Journal of Dermatology. 167(3). 668–677.
15.
Vincenti, Flavio, Stéphan Busque, Philip J. O’Connell, et al.. (2012). Randomized Phase 2b Trial of Tofacitinib (CP-690,550) in De Novo Kidney Transplant Patients: Efficacy, Renal Function and Safety at 1 Year. American Journal of Transplantation. 12(9). 2446–2456.
16.
Fleischmann, Roy, et al.. (2012). THU0153 Improvements in disease activity score by baseline status: Pooled analysis of five phase 3 studies with tofacitinib (CP-690,550) in patients with active rheumatoid arthritis. Annals of the Rheumatic Diseases. 71. 207–207.
17.
Isaacs, John D., Chudy I. Nduaka, S. Krishnaswami, et al.. (2012). AB0595 Changes in serum creatinine in patients with active rheumatoid arthritis treated with TOFACITINIB (CP-690,550). Annals of the Rheumatic Diseases. 71. 672–672.
18.
Weimar, Willem, Robert S. Gaston, Daniel C. Brennan, et al.. (2008). Phase 1 Dose-Escalation Study of CP-690 550 in Stable Renal Allograft Recipients: Preliminary Findings of Safety, Tolerability, Effects on Lymphocyte Subsets and Pharmacokinetics. American Journal of Transplantation. 8(8). 1711–1718.
19.
Krishnaswami, S., Günther Hochhaus, H Möllmann, Jeffrey T. Barth, & Hartmut Derendorf. (2005). Interpretation of absorption rate data for inhaled fluticasone propionate obtained in compartmental pharmacokinetic modeling. International Journal of Clinical Pharmacology and Therapeutics. 43(3). 117–122.
20.
Krishnaswami, S.. (2005). Pharmacokinetic profile of parecoxib sodium, an injectable prodrug of the Cox-2-selective inhibitor, valdecoxib. Clinical Pharmacology & Therapeutics. 77(2). P48–P48.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Mark Peterson Breakdown of academic impact, for papers by Edwin B. Cox Breakdown of academic impact, for papers by Randall E. Millikan Breakdown of academic impact, for papers by Denise Williams Breakdown of academic impact, for papers by Albiruni R. Abdul Razak Breakdown of academic impact, for papers by Ivo Kocák Breakdown of academic impact, for papers by Rastislav Bahleda Breakdown of academic impact, for papers by Liji Shen Breakdown of academic impact, for papers by Norbert Hollaender Breakdown of academic impact, for papers by J. Thaddeus Beck